Zydus Lifesciences Limited
NSE: ZYDUSLIFE BSE: ZYDUSLIFE
NSE
845.35
13.80 (1.66%)
Prev Close
831.55
Open Price
832.35
Volume
1,860,605
Today Low / High
830.25 / 847
52 WK Low / High
795 / 1324.3
Range
803 - 888
BSE
845.25
13.85 (1.67%)
Prev Close
831.4
Open Price
832.2
Volume
95,314
Today Low / High
830.05 / 846.95
52 WK Low / High
797.05 / 1323.9
Range
803 - 888
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 845.35 (target range: 803 - 888), reflecting a change of 13.8 (1.65955%). On the BSE, it is listed at 845.25 (target range: 803 - 888), showing a change of 13.85 (1.66586%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
21 Apr
832.35
1.56%
17 Apr
830.00
0.19%
16 Apr
883.15
-6.91%
15 Apr
889.80
-0.75%
11 Apr
863.85
0.58%
09 Apr
840.40
0.48%
08 Apr
845.00
1.67%
07 Apr
795.00
5.36%
04 Apr
901.90
-3.88%
03 Apr
949.65
-5.03%
02 Apr
870.25
2.40%
01 Apr
888.00
-1.18%
28 Mar
894.90
-0.95%
27 Mar
903.55
-1.42%
26 Mar
907.80
-0.03%
25 Mar
925.00
-1.91%
24 Mar
918.60
0.56%
Zydus Lifesciences Limited Graph
Zydus Lifesciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Zydus Lifesciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 845.35, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 845.25 | 853.70 | 768.33 - 939.07 |
| 862.16 | 689.72 - 1,034.59 | ||
| 870.61 | 609.43 - 1,131.79 | ||
| Bearish Scenario | 845.25 | 836.80 | 753.12 - 920.48 |
| 828.35 | 662.68 - 994.01 | ||
| 819.89 | 573.92 - 1,065.86 |
Overview of Zydus Lifesciences Limited
ISIN
INE010B01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,558,083
Market Cap
850,616,530,500
Last Dividend
3
Official Website
IPO Date
2002-07-01
DCF Diff
-249.25
DCF
1,092
Financial Ratios Every Investor Needs
Stock Dividend of ZYDUSLIFE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-07-26 | July 26, 24 | 3 | 3 | 2024-07-26 | 2024-09-08 | |
| 2023-07-27 | July 27, 23 | 6 | 6 | 2023-07-28 | 2023-09-10 | |
| 2022-07-28 | July 28, 22 | 2.5 | 2.5 | 2022-07-29 | 2022-08-16 | |
| 2021-07-28 | July 28, 21 | 3.5 | 3.5 | 2021-07-29 | 2021-09-10 | |
| 2020-03-23 | March 23, 20 | 3.5 | 3.5 | 2020-03-24 | 2020-04-15 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 19,547.40 Cr | 10,622.50 Cr | 8,924.90 Cr | 0.4566 | 1,312.50 Cr | 517.60 Cr | 4,539.50 Cr | 3,859.50 Cr | 38.14 | 5,622.20 Cr | 0.1974 |
| 2023-03-31 | 16,877.80 Cr | 6,310.10 Cr | 10,567.70 Cr | 0.6261 | 135.80 Cr | 582.90 Cr | 2,852.80 Cr | 1,960.30 Cr | 19.30 | 3,442.20 Cr | 0.1161 |
| 2022-03-31 | 14,827.60 Cr | 5,818.90 Cr | 9,008.70 Cr | 0.6076 | 114.60 Cr | 428.10 Cr | 2,474.10 Cr | 4,487.30 Cr | 17.65 | 3,671.00 Cr | 0.3026 |
| 2021-03-31 | 14,821.50 Cr | 5,480.00 Cr | 9,341.50 Cr | 0.6303 | 118.40 Cr | 472.10 Cr | 2,735.60 Cr | 2,133.60 Cr | 20.84 | 3,232.90 Cr | 0.1440 |
| 2020-03-31 | 13,812.10 Cr | 5,149.40 Cr | 8,662.70 Cr | 0.6272 | 89.70 Cr | 543.90 Cr | 2,101.80 Cr | 1,176.60 Cr | 11.49 | 2,524.50 Cr | 0.0852 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 413.00 Cr | 29,280.80 Cr | 7,179.20 Cr | 19,829.5000 Cr | 804.20 Cr | 391.20 Cr | 3,441.90 Cr | 6,914.80 Cr | 0.00 Cr | 0.00 Cr | 11.20 Cr | 5,341.9000 Cr |
| 2023-03-31 | 487.80 Cr | 25,756.40 Cr | 6,068.10 Cr | 17,515.8000 Cr | 1,194.90 Cr | 707.10 Cr | 3,413.30 Cr | 6,826.70 Cr | 1,960.10 Cr | 29.50 Cr | 927.30 Cr | 5,530.7000 Cr |
| 2022-03-31 | 657.80 Cr | 27,795.40 Cr | 8,741.60 Cr | 16,999.6000 Cr | 4,220.90 Cr | 3,563.10 Cr | 3,719.40 Cr | 6,422.60 Cr | 1,824.40 Cr | 28.70 Cr | 934.80 Cr | 7,839.4000 Cr |
| 2021-03-31 | 665.20 Cr | 23,884.70 Cr | 8,955.10 Cr | 12,992.3000 Cr | 4,607.60 Cr | 3,942.40 Cr | 3,236.20 Cr | 6,333.20 Cr | 1,648.30 Cr | 22.70 Cr | 631.20 Cr | 7,861.3000 Cr |
| 2020-03-31 | 845.30 Cr | 23,686.60 Cr | 11,976.20 Cr | 10,375.7000 Cr | 8,013.80 Cr | 7,168.50 Cr | 2,789.00 Cr | 6,193.70 Cr | 1,437.30 Cr | 7.60 Cr | 552.20 Cr | 8,269.4000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 3,227.9000 Cr | -1,475.2000 Cr | -1,810.4000 Cr | 2,321.3000 Cr | -74.8000 Cr | 413.0000 Cr | -906.6000 Cr | 3,859.5000 Cr | -392.9000 Cr | -621.0000 Cr | -2.0000 Cr |
| 2023-03-31 | 2,688.8000 Cr | 1,171.2000 Cr | -4,400.4000 Cr | 1,657.9000 Cr | -533.8000 Cr | 573.1000 Cr | -1,030.9000 Cr | 2,582.7000 Cr | -3,147.2000 Cr | -267.1000 Cr | 440.7000 Cr |
| 2022-03-31 | 2,104.1000 Cr | 1,154.4000 Cr | -868.3000 Cr | 901.5000 Cr | 2,372.9000 Cr | 3,460.1000 Cr | -1,202.6000 Cr | 5,232.3000 Cr | -383.7000 Cr | -372.2000 Cr | -525.5000 Cr |
| 2021-03-31 | 3,293.0000 Cr | -722.5000 Cr | -2,548.9000 Cr | 2,439.0000 Cr | -90.5000 Cr | 1,087.2000 Cr | -854.0000 Cr | 2,284.8000 Cr | -3,342.7000 Cr | -1.5000 Cr | -479.7000 Cr |
| 2020-03-31 | 2,505.4000 Cr | -1,012.3000 Cr | -1,094.2000 Cr | 1,601.3000 Cr | 398.9000 Cr | 1,177.7000 Cr | -904.1000 Cr | 1,495.4000 Cr | -348.9000 Cr | -856.9000 Cr | -101.0000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 5,123.50 Cr | 1,583.40 Cr | 3,540.10 Cr | 0.6910 | 976.00 Cr | 1,023.50 Cr | 10.17 | 1,445.10 Cr | 0.1998 |
| 2024-09-30 | 5,113.60 Cr | 1,471.40 Cr | 3,642.20 Cr | 0.7123 | 1,182.40 Cr | 911.20 Cr | 9.06 | 1,529.60 Cr | 0.1782 |
| 2024-06-30 | 6,207.50 Cr | 2,684.90 Cr | 3,522.60 Cr | 0.5675 | 1,893.90 Cr | 1,419.90 Cr | 14.11 | 2,147.20 Cr | 0.2287 |
| 2024-03-31 | 5,366.40 Cr | 1,611.50 Cr | 3,754.90 Cr | 0.6997 | 1,581.60 Cr | 1,182.30 Cr | 11.45 | 1,786.90 Cr | 0.2203 |
| 2023-12-31 | 4,343.70 Cr | 1,468.50 Cr | 2,875.20 Cr | 0.6619 | 945.30 Cr | 789.60 Cr | 7.80 | 1,140.10 Cr | 0.1818 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 1,061.40 Cr | 1,933.70 Cr | 2,995.10 Cr | 0.00 Cr | 3,716.90 Cr | 12,156.90 Cr | 7,153.10 Cr | 31,445.90 Cr | 7,291.30 Cr |
| 2024-03-31 | 413.00 Cr | 252.50 Cr | 1,357.60 Cr | 5,220.20 Cr | 3,441.90 Cr | 11,419.80 Cr | 6,914.80 Cr | 29,280.80 Cr | 7,179.20 Cr |
| 2023-12-31 | -1,519.50 Cr | 3,039.00 Cr | 1,519.50 Cr | 0.00 Cr | 0.00 Cr | 1,519.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 346.30 Cr | 1,671.20 Cr | 2,017.50 Cr | 3,915.20 Cr | 3,303.90 Cr | 9,934.80 Cr | 6,936.60 Cr | 25,879.40 Cr | 4,938.50 Cr |
| 2023-06-30 | -1,192.40 Cr | 2,384.80 Cr | 1,192.40 Cr | 0.00 Cr | 0.00 Cr | 1,192.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,182.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 789.60 Cr | 389.60 Cr | 0.00 Cr | 0.00 Cr | 389.60 Cr | 1,296.70 Cr | 907.10 Cr | 0.00 Cr | 389.60 Cr |
| 2023-09-30 | 800.70 Cr | 368.40 Cr | 0.00 Cr | 0.00 Cr | 368.40 Cr | 907.10 Cr | 538.70 Cr | 0.00 Cr | 368.40 Cr |
| 2023-06-30 | 1,086.90 Cr | 359.60 Cr | 0.00 Cr | 0.00 Cr | 359.60 Cr | 852.20 Cr | 492.60 Cr | 0.00 Cr | 359.60 Cr |
| 2023-03-31 | 296.60 Cr | 357.20 Cr | 0.00 Cr | 0.00 Cr | 357.20 Cr | 492.60 Cr | 135.40 Cr | 0.00 Cr | 357.20 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-10-06 | October 06, 15 | 5:1 |
| 2010-04-05 | April 05, 10 | 3:2 |
| 2006-08-30 | August 30, 06 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
President of Parenteral Operations
Mr. Vikram Shukla
Gender: male
Year Born: 1974
President & Chief Executive Officer of America
Mr. Punit Patel
Gender: male
Year Born:
Company Secretary & Compliance Officer
Mr. Dhaval Narendra Soni
Gender: male
Year Born:
MD & Executive Director
Dr. Sharvil Pankajbhai Patel
Gender: Not Specified
Year Born: 1979
Chief Operating Officer & Executive Director
Dr. Ganesh Narayan Nayak
Gender: Not Specified
Year Born: 1955
Chief Financial Officer
Mr. Nitinkumar Dalsukhray Parekh
Gender: male
Year Born:
Head of Investor Relations
Mr. Arvind Bothra
Gender: male
Year Born:
FAQs about Zydus Lifesciences Limited
Who is the CEO of the company?
The CEO is Mr. Punit Patel.
What is the current market price of the stock?
The current price is ₹845.35.
What is the 52-week price range?
The range is ₹795-1324.3.
What is the market capitalization of the company?
The market capitalization is ₹85,061.65 crores.
What is the dividend yield?
The dividend yield is 0.35%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 18.75.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Zydus Lifesciences Limited (ISIN: INE010B01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹85,061.65 crores and an average daily volume of 1,558,083 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹3.